In all patients with tissue−ctDNA+ tumors, tumor tissue samples were obtained before the initiation of anti-epidermal growth factor receptor (EGFR) therapy, whereas plasma samples were collected after progression on anti-EGFR therapy. Here, EGFR is linked to neoplasm.